Trials soon ready
Clinical trials expected to report results within the next 3 months, ranked by potential. Each trial shows its estimated finish date — explained in plain language.
-
Could a Virus-Like particle vaccine outsmart polio?
⭐️ VACCINE ⭐️ OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots
⭐️ VACCINE ⭐️ Recruiting nowThe main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in th…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
InVivyd · IVVD NASDAQ Trade on eToro (ad) -
New RSV vaccine candidate aims to shield older adults from severe lung infections
⭐️ VACCINE ⭐️ Recruiting nowThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 23, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
New yellow fever vaccine trial for kids could boost global protection
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and when they are co-administered with Measles Mumps Rub…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New RSV vaccine trial targets High-Risk adults in japan
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways. The study is seeking participants who are: * 18 to 59 years of age * adu…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New 24-Valent vaccine aims to shield children from more pneumonia strains
⭐️ VACCINE ⭐️ Recruiting nowA Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenici…
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:06 UTC
Sinovac Biotech Ltd. · SVA NASDAQReward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial
⭐️ VACCINE ⭐️ OngoingThe purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate …
Results expected Sep 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:03 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
RSV booster study aims to keep seniors safe for five seasons
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vac…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 31, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New vaccine aims to protect african children from deadly salmonella
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Ty…
Results expected Sep 2026 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:35 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Pregnancy vaccine shields newborns from RSV: Real-World data reveals impact
⭐️ VACCINE ⭐️ OngoingThis study will be conducted in collaboration with a research network of independent hospital sites to evaluate the vaccine effectiveness (VE) and impact of ABRYSVO vaccination during pregnancy in a real-world population over multiple seasons, which began in 2024 across Argentina…
Results expected Oct 2026 (estimated)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:34 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
BioNTech launches first human test of mRNA herpes vaccine
⭐️ VACCINE ⭐️ OngoingThis exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2 genital herpes. Part A will focus on the safety ev…
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:55 UTC
BioNTech SE · BNTX NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Could a Freeze-Dried vaccine shield all ages from hib?
⭐️ VACCINE ⭐️ OngoingThis trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of…
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Could this mRNA vaccine stop the virus behind mono and certain cancers?
⭐️ VACCINE ⭐️ OngoingThe main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adole…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Moderna launches first human test of mRNA vaccine against Epstein-Barr virus
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New meningitis vaccine for kids shows promise in large trial
⭐️ VACCINE ⭐️ OngoingThe goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years. The main questions it aims to answer are: Is the immune response induced by the investigationa…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
Sinovac Biotech Co., Ltd. · SVA NASDAQReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New Needle-Freeze? muscle shot chickenpox vaccine tested in toddlers
⭐️ VACCINE ⭐️ Recruiting nowThis study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Add…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works ModerateA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
5,000 volunteers tracked to see if chikungunya vaccine is safe
⭐️ VACCINE ⭐️ OngoingThis is an observational study with primary data collection, which will combine a prospective safety cohort study and an SCRI study.
Results expected Oct 2026 (estimated)
Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 23, 2026 00:00 UTC
Valneva SE · VALN NASDAQ Trade on eToro (ad)Reward if it works ModerateAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New chickenpox vaccine trial aims to protect 300 kids
⭐️ VACCINE ⭐️ Not yet recruitingThis is a single armed, Phase 3 study to assess the immunogenicity and safety of the varicella vaccine manufactured by Sinovac. A total of 300 healthy participants aged 1-12 years will be enrolled. All participants will receive a single dose of varicella vaccine manufactured by S…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:07 UTC
Sinovac Biotech Ltd. · SVA NASDAQReward if it works ModerateA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New vaccine trial aims to shield korean babies from deadly meningitis
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to assess the safety and immune responses of rMenB+OMV NZ vaccine when administered to healthy infants from 2 months in the Republic of Korea according to a 2-dose primary schedule and 1 booster dose.
Results expected Sep 2026 (estimated)
Phase: PHASE4 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:04 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works LowAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Polio vaccine showdown: which sequence protects best?
⭐️ VACCINE ⭐️ Recruiting nowThe goal of this study is to compare the immunogenicity and safety of sIPV administered via subcutaneous and intramuscular injection routes
Results expected Sep 2026 (estimated)
Phase: PHASE4 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:00 UTC
Sinovac Biotech Co., Ltd. · SVA NASDAQReward if it works LowAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Massive study of 22 million seniors tests pneumonia Vaccine's Real-World power
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia (a bacterial lung disease caused by the germ Strepto…
Results expected Oct 2026 (estimated)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works LowAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New TB vaccine trial aims to shield millions
⭐️ VACCINE ⭐️ OngoingThis is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a rat…
Results expected Aug 2026 (estimated)
Phase: PHASE1 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:25 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works LowAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
New meningitis vaccine enters first human tests
⭐️ VACCINE ⭐️ Not yet recruitingThis trial adopts an open-label design combined with randomized, blinded, placebo-controlled and active-controlled design. The purpose of this trial is to evaluate the safety and immunogenicity of a Group ACYW135X Meningococcal Conjugate Vaccine. This study is planned to enroll 1…
Results expected Sep 2026 (estimated)
Phase: PHASE1 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
Sinovac Biotech Ltd. · SVA NASDAQReward if it works LowAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to a broker we have a commercial relationship with, and we may earn a commission if you open an account. This never affects which trials are listed or how they are ranked.